TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35287967
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg intravenously q4w and olaparib 300 mg 2dd until disease progression, unacceptable toxicity, or patient withdrawal
Study: 35287972
Drug: PCSK9 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCSK9 inhibitors (overall)
Study: 35288468
Drug: Itacitinib (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib (100-400 mg once a day) plus epacadostat (50-300 mg two times per day)
Study: 35288468
Drug: Itacitinib (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib (100-400 mg once a day) plus parsaclisib (0.3-10 mg once a day)
Study: 35288511
Drug: AI-graded daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI-graded daily average BSS scores
Study: 35289267
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of maximum standardised uptake value and peak enhancement
Study: 35289310
Drug: Antiphospholipid antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiphospholipid antibodies
Study: 35290461
Drug: School-based screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based screening and treatment with artemether-lumefantrine
Study: 35291289
Drug: 100-μg mRNA-1273
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-μg mRNA-1273 booster dose
Study: 35291289
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (second dose of mRNA-1273)
Study: 35291977
Drug: Lapatinib 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,250 mg orally once per day continuously plus capecitabine (1,000 mg/m2)
Study: 35292609
Drug: Dose adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose adjustment based on TDM measurements
Study: 35292724
Drug: Avelumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (10 mg/kg every 2 weeks)
Study: 35293984
Drug: Pegloticase (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase (8 mg biweekly infusions) + oral MTX (15 mg/week) co-therapy
Study: 35294522
Drug: Ribociclib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib + binimetinib (binimetinib 45 mg twice daily + ribociclib 200 mg once daily, 21 days on/7 days off)
Study: 35294527
Drug: Systemic treatments
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatments (44 patients, 8.5%)
Study: 35294811
Drug: Valoctocogene roxaparvovec
Normalized name: Valoctocogene roxaparvovec
DrugBank: Valoctocogene roxaparvovec (DB15561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) gene therapy, single infusion of 6×10^13 vg/kg
Study: 35294811
Drug: Valoctocogene roxaparvovec
Normalized name: Valoctocogene roxaparvovec
DrugBank: Valoctocogene roxaparvovec (DB15561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) gene therapy
Study: 35295414
Drug: Neuromodulation (intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromodulation (intrathecal therapy, spinal cord stimulation, or dorsal root ganglion stimulation)
Study: 35295414
Drug: Pain medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medications
Study: 35295414
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (medications)
Study: 35295488
Drug: Probiotic VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic VSL#3 Treatment
Study: 35295665
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of intravenous amoxicillin (HDIVA)
Study: 36043180
Drug: Regdanvimab 40
Normalized name: Regdanvimab
DrugBank: Regdanvimab (DB16405)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Regdanvimab 40 mg/kg
Study: 35295819
Drug: Regdanvimab 80
Normalized name: Regdanvimab
DrugBank: Regdanvimab (DB16405)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Regdanvimab 80 mg/kg
Study: 35296254
Drug: Psychotropic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic drugs (PDs)
Study: 35296254
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate medications
Study: 35296254
Drug: Antipsychotics, antidepressants,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics, antidepressants, and sedative substances
Study: 35296254
Drug: Pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication
Study: 35296254
Drug: Antipsychotics and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics and sedative substances
Study: 35296895
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 10-minute Apgar score with other risk variables
Study: 35296961
Drug: Ophthalmological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmological treatment
Study: 35297025
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg subcutaneous injection every 2 weeks
Study: 35297944
Drug: Any adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any adjuvant chemotherapy
Study: 35297944
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least 4 cycles of adjuvant platinum-based chemotherapy
Study: 35297944
Drug: Any cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any cisplatin-based adjuvant chemotherapy
Study: 35298296
Drug: Cabozantinib 40
Normalized name: cabozantinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 40 mg once daily plus nivolumab 240 mg once every 2 weeks (Cohort 1)
Study: 35298296
Drug: Cabozantinib 40
Normalized name: cabozantinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 40 mg once daily plus nivolumab 480 mg once every 4 weeks (Cohort 1)
Study: 35298698
Drug: Cetrelimab 80,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrelimab 80, 240, 460, or 800 mg every 2 weeks (Q2W) or 480 mg Q4W (Phase 1)
Study: 35298698
Drug: Cetrelimab 240
Normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrelimab 240 mg Q2W (Phase 2)
Study: 35299035
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus capecitabine (third or fourth-line treatment)
Study: 35299273
Drug: Near-infrared (NIR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Near-infrared (NIR) contrast agent labeled with IRDye800 administered topically to patients with Barrett's esophagus.
Study: 35299970
Drug: Abnormal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abnormal glucose metabolism parameters (including DM, hyperinsulinemia, and insulin resistance)
Study: 35299970
Drug: Postprandial 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial 2 h blood glucose ≥11.1mmol/L and HbA1c ≥6.5%
Study: 35301822
Drug: Brolucizumab 6
Normalized name: BROLUCIZUMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [BEOVU]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brolucizumab 6 mg intravitreal injection
Study: 35302585
Drug: ARRY-382 200-400
Normalized name: ARRY-502
DrugBank: ARRY-502 (DB16053)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARRY-382 200-400 mg QD plus pembrolizumab 2 mg/kg IV Q3W (Phase 1b)
Study: 35302585
Drug: ARRY-382 300
Normalized name: ARRY-502
DrugBank: ARRY-502 (DB16053)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARRY-382 300 mg QD plus pembrolizumab 200 mg IV Q3W (Phase 2)
Study: 35303007
Drug: CAR-T IS
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T IS quality measurement using ML-based method
Study: 35303007
Drug: ML-based automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-based automated algorithm for quantifying CAR-T IS data
Study: 35303070
Drug: Zanubrutinib 160
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 160 mg orally twice daily
Study: 35303201
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of Daily Living (ADL) score (0=disability, 6=no disability)
Study: 35304622
Drug: Camrelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (200 mg IV on day 1), Apatinib (500 mg oral once daily), S-1 (specific dose oral for first 14 days)
Study: 35304622
Drug: Camrelizumab, Apatinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab, Apatinib, and S-1 combination therapy
Study: 35304684
Drug: Adalimumab biosimilar
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab biosimilar PF-06410293 (ADL-PF) 40 mg via prefilled syringe (PFS) and single-use PFP device
Study: 35305102
Drug: Toripalimab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (240 mg, day 1) plus paclitaxel (135 mg/m2, day 1) and carboplatin (AUC 5 mg/mL per min, day 1) for 2 cycles
Study: 35305400
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg intravenously every 3 weeks until loss of clinical benefit or unacceptable toxicity
Study: 35305556
Drug: Non-nephrotoxic antibiotic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nephrotoxic antibiotic
Study: 35305740
Drug: Ad26.COV2.S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.COV2.S vaccine (Johnson & Johnson), single dose of 5×10^10 viral particles
Study: 35306029
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (non-stent)
Study: 35306553
Drug: Mesalazine ≥4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine ≥4 g/day
Study: 35306553
Drug: Mesalazine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine treatment duration >6 months
Study: 35306553
Drug: Mesalazine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine treatment duration 3-6 months
Study: 35306594
Drug: Sinovac-CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinovac-CoronaVac vaccine (two doses 28 days apart, D0/D28)
Study: 35307611
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg once daily in continuous 21-day cycles (cohort 1)
Study: 35307611
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg once daily in continuous 21-day cycles (cohort 2)
Study: 35307611
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg once daily in continuous 21-day cycles
Study: 35307972
Drug: Avelumab, axitinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab, axitinib, and palbociclib (DL1: avelumab 10 mg/kg IV q2weeks, axitinib 3 mg po bid, palbociclib 75 mg po daily for 7 days off/21 days on)
Study: 35307972
Drug: Avelumab, axitinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab, axitinib, and palbociclib combination
Study: 35308034
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of convalescent plasma (Low-volume)
Study: 35308034
Drug: 400 mL
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL of convalescent plasma (High-volume)
Study: 35308099
Drug: N8-GP (turoctocog
Approvals — FDA: no, EMA: no, PMDA: no
Description: N8-GP (turoctocog alfa pegol) prophylaxis administered intravenously for up to 104 weeks, every 7 days, twice weekly, or three times weekly.
Study: 35308376
Drug: 3HP treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3HP treatment (once-weekly rifapentine plus isoniazid for 3 months)
Study: 35308535
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 40 mg intravenous dexamethasone
Study: 35309087
Drug: Amcenestrant 200
Normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amcenestrant 200 mg plus palbociclib 125 mg
Study: 35309087
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg plus palbociclib 125 mg
Study: 35310961
Drug: Cytoreductive nephrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive nephrectomy (CN) after starting systemic immune checkpoint-based combination therapy
Study: 35310961
Drug: Continued systemic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued systemic therapy (control group)
Study: 35313819
Drug: Wearable activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable activity tracker (Fitbit InspireHR) used for 12 weeks with personalized activity goals and weekly feedback
Study: 35313957
Drug: Eye Tracking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Tracking (ET) tasks including Activity Monitoring, Social Interactive, Static Social Scenes, Biological Motion Preference, and Pupillary Light Reflex tasks
Study: 35314693
Drug: Palbociclib 125
Normalized name: palbociclib 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 125 mg, 5-days-on/2-days-off, plus letrozole or fulvestrant
Study: 35315601
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 3 years in idiopathic GHD patients
Study: 35315601
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 3 years in organic GHD patients
Study: 35315601
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 3 years in both idiopathic and organic GHD patients
Study: 35315783
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment protocol (20 treatments over 4 weeks) with an intensity of 120% of resting motor threshold, frequency of 10 Hz, 10 trains of 60 pulses per train (total of 600 pulses), intertrain interval of 45 seconds.
Study: 35315783
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS) treatment.
Study: 35316227
Drug: Various pharmacological
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various pharmacological interventions including antivirals, antimalarials, corticosteroids, NSAIDs, and antipyretics
Study: 35316227
Drug: COVID-19 vaccines
Normalized name: Covid-19 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccines (Pfizer/BioNTech and mRNA-1273 Moderna)
Study: 35316328
Drug: Nivolumab alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab alone (240 mg every 2 weeks for up to 6 cycles)
Study: 35316328
Drug: Nivolumab alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab alone or in combination with NICE
Study: 35316922
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 or 150 mg every 2 weeks for ≥ 3 to ≤ 30 months
Study: 35317413
Drug: Tablet-based Tanzania
Normalized name: influenza A virus A/Tasmania/503/2020 (H3N2) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based Tanzania 24-hour recall tool (TZ-24hr-DR)
Study: 35317851
Drug: SCONE™ therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCONE™ therapy (transcutaneous spinal cord neuromodulation)
Study: 35318970
Drug: Gadopiclenol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadopiclenol at a dose of 0.05 mmol/kg
Study: 35319502
Drug: Opioids coprescribed
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids coprescribed with antidepressants interacting with CYP2D6
Study: 35319502
Drug: Predicted phenotypes
Normalized name: Proliferation arrested myelomonocytic leukemic cell line-derived cells with a mature dendritic cell phenotype
DrugBank: DCP-001 (DB17423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predicted phenotypes and drug-drug interactions
Study: 35320878
Drug: Myosuit (robotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myosuit (robotic assistance) during activities of daily life (ADL)
Study: 35320878
Drug: No robotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No robotic assistance during activities of daily life (ADL)
Study: 35321427
Drug: Dalpiciclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib (125 mg), Pyrotinib (400 mg), Letrozole (2.5 mg)
Study: 35321427
Drug: Dalpiciclib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib (100 mg), Pyrotinib (400 mg), Letrozole (2.5 mg)
Study: 35321427
Drug: Dalpiciclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib (125 mg), Pyrotinib (320 mg), Letrozole (2.5 mg)
Study: 35321427
Drug: Study treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment (1L HER2-targeted therapy)
Study: 35321427
Drug: Study treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment (2L HER2-targeted therapy)
Study: 35321427
Drug: Study treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment (2L setting)
Study: 35321744
Drug: Somatocognitive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatocognitive therapy (SCT)
Study: 35321744
Drug: Standard PVD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PVD treatment
Study: 35321895
Drug: Pfizer BNT162b2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer BNT162b2 mRNA COVID-19 vaccine, 1 dose, administered within 4 days of enrolment
Study: 35322287
Drug: Copanlisib 60
Normalized name: copanlisib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib 60 mg intravenous infusion on days 1, 8, and 15 of a 28-day cycle
Study: 35322330
Drug: Contact Force
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contact Force (CF) > 25 g
Study: 35322535
Drug: Ready-to-use room
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-use room temperature liquid stable formulation of glucagon
Study: 35322535
Drug: Lyophilised formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilised formulation of glucagon
Study: 35323379
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Social Skills Training (CBSST) with intranasal oxytocin
Study: 35323885
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention (oral and written education about LB)
Study: 35323905
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral dydrogesterone (DYD) ter-in-die (tid) for luteal support
Study: 35323932
Drug: Clinical prediction
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical prediction model containing soluble urokinase plasminogen activator receptor (suPAR)
Study: 35324095
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antipsychotic treatment)
Study: 35325211
Drug: JNJ-74699157 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-74699157 (100 mg)
Study: 35325211
Drug: JNJ-74699157 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-74699157 (200 mg)
Study: 35325225
Drug: Lenvatinib (MTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (MTD 24 mg) with capecitabine-based chemoradiation
Study: 35326718
Drug: TTFields/sorafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFields/sorafenib (150 kHz for ≥18 h/day with sorafenib 400 mg BID)
Study: 35331504
Drug: Nutrition-focused quality
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition-focused quality improvement program (QIP) including education on macro- and micronutrient intake and physical exercise, dietary counseling, and provision of oral nutritional supplements (ONS) for daily intake over 60 days.
Study: 35331634
Drug: Vestronidase alfa
Normalized name: Vestronidase alfa
DrugBank: Vestronidase alfa (DB12366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vestronidase alfa 4 mg/kg by intravenous infusion every other week for 48 weeks
Study: 35332036
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation (radiosurgery) targeting the retroperitoneal coeliac plexus nerve bundle with a single fraction of 25 Gy
Study: 35332134
Drug: Antidepressant (escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant (escitalopram 20 mg/day)
Study: 35332134
Drug: Antidepressant plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant plus COX-2 inhibitor (celecoxib)
Study: 35332278
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SOC) therapy, median 4.0 cycles (range, 1-20)
Study: 35332278
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SOC) therapy
Study: 35332334
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of COVID-19 vaccine
Study: 35332334
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of COVID-19 vaccine
Study: 35332334
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of COVID-19 vaccine
Study: 35332334
Drug: Full vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full vaccination (two doses)
Study: 35333110
Drug: AAVrh10 or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAVrh10 or AAV9 (systemic or CSF administration)
Study: 35337339
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of famitinib (angiogenesis inhibitor), camrelizumab (PD-1 monoclonal antibody), and chemotherapy